Comparative cost per responder analysis of Ciltacabtagene autoleucel and real-world standard of Care therapy in patients with lenalidomide-refractory multiple myeloma.

Key Points

• Evaluate the cost-effectiveness and clinical benefits of ciltacabtagene autoleucel versus standard care for refractory multiple myeloma.
• Utilized a CPR model for cost per responder analysis
• Compared ciltacabtagene autoleucel with real-world standard of care
• Focused on lenalidomide-refractory multiple myeloma patients
• Ciltacabtagene autoleucel demonstrated substantial clinical benefits over standard therapies
• Economic analysis revealed cost advantages for cilta-cel in treating refractory multiple myeloma